Table 2.

Univariate Cox regression analysis of variables influencing overall survival in patients with inflammatory breast cancer

	Adjusted Hazard Ratio	95% Confidence Interval	P value
Year group
Before 10/2006	1.00 (Reference)
After 10/2006	0.50	(0.34-0.94)	0.03
Molecular receptor expression type
Basal	1.00
Luminal A	0.23	(0.12-0.41)	<0.001
Luminal B	0.37	(0.17-0.79)	0.01
HER2	0.49	(0.29-0.83)	0.008
% nodes positive
≥ 20%	1.0
< 20%	0.42	(0.25-0.70)	0.001
Radiation dose (continuous)	0.94	(0.90-0.98)	0.003
Radiation treatment
Yes	1.00
No	5.01	(2.69-9.35)	<0.001
Estrogen receptor+
Yes	1.00
No	2.74	(1.64-4.57)	<0.001
Hormone therapy for estrogen receptor+ disease	1.00
Yes	4.61	(2.54-8.37)	<0.001
No
Lymphovascular invasion
Yes	1.00
No	0.56	(0.34-0.92)	0.02
Grade
Grade 3	1.00
Grade 1 or 2	0.29	(0.14-0.61)	0.001
Pathologic complete response
Yes	1.00
No	3.55	(1.55-8.15)	0.003
Extracapsular extension
Yes	1.00
No	0.57	(0.34-0.94)	0.03
PET/CT used in initial staging
Yes	1.00
No	0.69	(0.39-1.21)	0.20
Race
African-American	1.00
Other	1.18	(0.72-1.94)	0.51
Taxane received
Yes	1.00
No	3.47	(0.85-14.24)	0.08
HER2
Yes	1.00
No	1.12	(0.072-1.75)	0.61
Neoadjuvant trastuzumab in HER2 +
Yes	1.00
No	2.16	(0.66-7.06)	0.20

Abbreviations: PET/CT, positron emission tomography - computed tomography Other factors that were not significant in the univariate analysis were race, age, menopause status, HER2 status, fraction schedule, and surgical margin